Special Issue "Clinical Proteomics: Third Edition"

A special issue of Proteomes (ISSN 2227-7382).

Deadline for manuscript submissions: 30 June 2022 | Viewed by 176

Special Issue Editors

Dr. Edwin Lasonder
E-Mail Website
Guest Editor
Department of Applied Sciences, Faculty of Life and Health Sciences, Northumbria University, Newcastle-Upon-Tyne NE1 8ST, UK
Interests: mass spectrometry-based proteomics; malaria; Plasmodium falciparum; red blood cells; cancer; phosphorylation; signalling pathways; clinical proteomics
Special Issues, Collections and Topics in MDPI journals
Dr. Vikram Sharma
E-Mail Website
Guest Editor
School of Biomedical Sciences, University of Plymouth, Plymouth PL4 8AA, UK
Interests: proteomics; mass spectrometry; signaling pathways; cancer; phosphorylation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the post-genome era, ‘omics’ technologies are key to our understanding of human disease because these technologies provide a global approach rather than studying single genes/proteins by traditional biochemical approaches. This Special Issue is dedicated to covering the area of clinical proteomics and translational mass-spectrometry-based proteomics research. This typically involves protein profiling of human cells and tissues in health and disease state for the detection of diagnostic and prognostic biomarkers, or for developing mechanistic insights into disease pathogenicity. An important advantage of the global proteome approach is that it provides an overall catalogue of differentially expressed proteins in body fluids, cells, and tissues that define disease phenotypes in patients, which can contribute to individualized treatments. Recent advancements in modern mass spectrometers regarding sensitivity, sequencing methods (DDA, DIA), and quantification approaches of clinical samples (label-free quantification, multiplex quantitation via isobaric chemical tags, and absolute quantification via SRM/MRM technology) enable deep proteome coverage of clinical samples, which is an important prerequisite for personalized medicine.

In this Special Issue of Proteomes, we are looking forward to original research studies on proteome analysis of disease-related samples and welcome the submission of review articles covering recent developments in clinical proteomics.

Dr. Edwin Lasonder
Dr. Vikram Sharma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Proteomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Clinical proteomics 
  • Disease 
  • Body fluids and tissue 
  • Personalized medicine 
  • Quantitative proteomics

Published Papers

This special issue is now open for submission.
Back to TopTop